Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine

Por Graham, Donna M., Leighl, Natasha B.
Publicado em 2014

Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine

Por Soldera, Sara Victoria, Leighl, Natasha B.
Publicado no Front Oncol (2017)

Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?—current evidence and future perspectives

Por O’Kane, Grainne M., Leighl, Natasha B.
Publicado no Transl Lung Cancer Res (2016)

Ancillary Testing in Lung Cancer Diagnosis

Por Dubinski, William, Leighl, Natasha B., Tsao, Ming-Sound, Hwang, David M.
Publicado em 2012

Targeting the KRAS Pathway in Non-Small Cell Lung Cancer

Por Tomasini, Pascale, Walia, Preet, Labbe, Catherine, Jao, Kevin, Leighl, Natasha B.
Publicado no Oncologist (2016)

Do Economic Evaluations of Targeted Therapy Provide Support for Decision Makers?

Por Ferrusi, Ilia L., Leighl, Natasha B., Kulin, Nathalie A., Marshall, Deborah A.
Publicado em 2011

Do Economic Evaluations of Targeted Therapy Provide Support for Decision Makers?

Por Ferrusi, Ilia L., Leighl, Natasha B., Kulin, Nathalie A., Marshall, Deborah A.
Publicado em 2011

Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS

Por Korpanty, Grzegorz J., Graham, Donna M., Vincent, Mark D., Leighl, Natasha B.
Publicado em 2014

The Value of Personalizing Medicine: Medical Oncologists’ Views on Gene Expression Profiling in Breast Cancer Treatment

Por Bombard, Yvonne, Rozmovits, Linda, Trudeau, Maureen, Leighl, Natasha B., Deal, Ken, Marshall, Deborah A.
Publicado no Oncologist (2015)

Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses

Por Ferrusi, Ilia L, Marshall, Deborah A, Kulin, Nathalie A, Leighl, Natasha B, Phillips, Kathryn A
Publicado em 2009

Development and evaluation of a decision aid for patients considering first‐line chemotherapy for metastatic breast cancer

Por Chiew, Kimberly S., Shepherd, Heather, Vardy, Janette, Tattersall, Martin H.N., Butow, Phyllis N., Leighl, Natasha B.
Publicado no Health Expect (2007)

Monitoring and Management of Immune‐Related Adverse Events Associated With Programmed Cell Death Protein‐1 Axis Inhibitors in Lung Cancer

Por O'Kane, Grainne M., Labbé, Catherine, Doherty, Mark K., Young, Kelvin, Albaba, Hamzeh, Leighl, Natasha B.
Publicado no Oncologist (2016)

Quality-Adjusted Time Without Symptoms or Toxicity Analysis of Adjuvant Chemotherapy in Non–Small-Cell Lung Cancer: An Analysis of the National Cancer Institute of Canada Clinical...

Por Jang, Raymond W., Le Maître, Aurélie, Ding, Keyue, Winton, Tim, Bezjak, Andrea, Seymour, Lesley, Shepherd, Frances A., Leighl, Natasha B.
Publicado em 2009

Closing the Personalized Medicine Information Gap: HER2 Test Documentation Practice

Por Ferrusi, Ilia L., Earle, Craig C., Trudeau, Maureen, Leighl, Natasha B., Pullenayegum, Eleanor, Khong, Hoa, Hoch, Jeffrey S., Marshall, Deborah A.
Publicado em 2013

Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Cli...

Por Leighl, Natasha B., Rekhtman, Natasha, Biermann, William A., Huang, James, Mino-Kenudson, Mari, Ramalingam, Suresh S., West, Howard, Whitlock, Sara, Somerfield, Mark R.
Publicado no J Clin Oncol (2014)

A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium

Por Taylor, Sara K., Chia, Stephen, Dent, Susan, Clemons, Mark, Agulnik, Mark, Grenci, Pamela, Wang, Lisa, Oza, Amit M., Ivy, Percy, Pritchard, Kathleen I., Leighl, Natasha B.
Publicado em 2010

Barriers and Challenges to Global Clinical Cancer Research

Por Seruga, Bostjan, Sadikov, Aleksander, Cazap, Eduardo L., Delgado, Lucia Beatriz, Digumarti, Raghunadharao, Leighl, Natasha B., Meshref, Mohamed M., Minami, Hironobu, Robinson, Eliezer, Yamaguchi, Nise Hitomi, Pyle, Doug, Cufer, Tanja
Publicado em 2014

Utilization and costs of home care for patients with colorectal cancer: a population-based study

Por Mittmann, Nicole, Liu, Ning, Porter, Joan, Seung, Soo Jin, Isogai, Pierre K., Saskin, Refik, Cheung, Matthew C., Leighl, Natasha B., Hoch, Jeffrey S., Trudeau, Maureen, Evans, William K., Dainty, Katie N., Earle, Craig C.
Publicado em 2014

A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer

Por Sacher, Adrian G., Le, Lisa W., Lara-Guerra, Humberto, Waddell, Thomas K., Sakashita, Shingo, Chen, Zhuo, Kim, Lucia, Zhang, Tong, Kamel-Reid, Suzanne, Salvarrey, Alexandra, Darling, Gail, Yasufuku, Kazuhiro, Keshavjee, Shaf, de Perrot, Marc, Shepherd, Frances A., Liu, Geoffrey, Tsao, Ming Sound, Leighl, Natasha B.
Publicado no Oncotarget (2016)

Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients

Por Martin, Petra, Shiau, Carolyn J, Pasic, Maria, Tsao, Ming, Kamel-Reid, Suzanne, Lin, Stephanie, Tudor, Roxana, Cheng, Susanna, Higgins, Brian, Burkes, Ronald, Ng, Matilda, Arif, Saroosh, Ellis, Peter M, Hubay, Stacy, Kuruvilla, Sara, Laurie, Scott A, Li, Jing, Hwang, David, Lau, Anthea, Shepherd, Frances A, Le, Lisa W, Leighl, Natasha B
Publicado no Br J Cancer (2016)